Thanos Zomas, MD of @TakedaOncology discusses brentuximab vedotin with chemotherapy for stage 3/4 classical hodgkin lymphoma (cHL): 4-year update of the echelon-1 study.
4-Year Update of the Echelon-1 Study #ASH19 #ASH @TakedaOncology
Thanos Zomas, MD of @TakedaOncology discusses brentuximab vedotin with chemotherapy for stage 3/4 classical hodgkin lymphoma (cHL): 4-year update of the echelon-1 study.